Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab-based chemoimmunotherapy for resectable Pancoast NSCLC
2022-003717-11Phase 2Active
- Sponsor
- Fundación GECP
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC) and lung superior sulcus carcinoma, sponsored by Fundación GECP. Primary endpoint: Complete resection (R0) rate after induction treatment. Started Jan 2023; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)lung superior sulcus carcinoma
Beyond the preview
Go deeper on 2022-003717-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003717-11.